Advanced search
1 file | 83.61 KB

A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants

(2000) CLINICAL TRANSPLANTATION. 14(4, part 1). p.340-344
Author
Organization
Abstract
Acute rejection remains a major problem in simultaneous pancreas-kidney (SPK) transplant and occurs in 60-100% of the cases. With the introduction of mycophenolate mofetil (MMF) replacing azathioprine (AZA) as a basis immunosuppressant, reduced rates of rejection have been reported. This study investigates the frequency and clinical relevance of allograft rejection in SPK patients receiving antithymocyte globulin (ATG) or Basiliximab(R) induction therapy and cyclosporine Neoral(R) (CyA), MMF, steroid basis immunosuppression. Between December 1996 and October 1999, 21 consecutive patients (15 males, 6 females) received a SPK transplant at our institution with a mean +/- standard deviation (SD) age of 42 +/- 6 yr. Of these, 14 patients were treated with anti-thymocyte globulin (ATG) Fresenius(R) (rabbit) 3-5 mg/kg for 6 +/- 2 d, cyclosporine Neoral (CyA) (trough levels 350-400 ng/mL), MMF 3 g/d and low dose steroid therapy. Seven SPK patients were treated with Basiliximab (Simulect(R), Novartis 20 mg on d 0 and d 4 post-transplant) instead of ATG. The patients had an average human leucocyte antigen (HLA) mismatch of 3.9/6 and a negative cross match. All patients remained on triple drug therapy. Three patients were switched to tacrolimus instead of Neoral for CyA intolerance. The mean +/- SD cold ischemia time (CIT) of the organs was 10.1 +/- 2.4 h for the pancreas and 10.5 +/- 2.6 h for the kidney. Results: Biopsy-proven rejection occurred in the kidney of 1 ATG patient (8%), which responded to steroid bolus therapy. One of the patients (14%) with Basiliximab induction developed renal allograft rejection, which was resolved after a 6-d course of anti-CD3 mAb (OKT3) treatment. All patients (100%) were free from rejection in the pancreas, as measured by urine amylase levels and glycemic control without the need for exogenous insulin with a mean glycosylated hemoglobin (HBA(1)C) of 5.1 +/- 0.7% and serum creatinine with a mean of 1.24 +/- 0.24 mg/dL in a mean follow-up period of 17 +/- 15 months (median 12, range 2-37). Conclusion: Triple drug immunosuppression including cyclosporine, MMF and low dose steroids with ATG or interleukin 2 (IL2) receptor antibodies induction therapy appears to be a very suitable immunosuppressive regimen for combined pancreas-kidney transplant (PKT) with a marked reduction in the incidence of rejection.
Keywords
Basiliximab, ATG, cyclosporine, mycophenolate mofetil, rejection, simultaneous pancreas-kidney transplant, CADAVERIC KIDNEY, TACROLIMUS, INFECTION, REJECTION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 83.61 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Hesse, Uwe, Roberto Troisi, B Jacobs, Bruno Van Vlem, Bernard de Hemptinne, Raymond AMG Van Holder, Frank Vermassen, J De Roose, and Norbert Lameire. 2000. “A Single Center’s Clinical Experience with Quadruple Immunosuppression Including ATG or IL2 Antibodies and Mycophenolate Mofetil in Simultaneous Pancreas-kidney Transplants.” Clinical Transplantation 14 (4, part 1): 340–344.
APA
Hesse, U., Troisi, R., Jacobs, B., Van Vlem, B., de Hemptinne, B., Van Holder, R. A., Vermassen, F., et al. (2000). A single center’s clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. CLINICAL TRANSPLANTATION, 14(4, part 1), 340–344.
Vancouver
1.
Hesse U, Troisi R, Jacobs B, Van Vlem B, de Hemptinne B, Van Holder RA, et al. A single center’s clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. CLINICAL TRANSPLANTATION. 2000;14(4, part 1):340–4.
MLA
Hesse, Uwe, Roberto Troisi, B Jacobs, et al. “A Single Center’s Clinical Experience with Quadruple Immunosuppression Including ATG or IL2 Antibodies and Mycophenolate Mofetil in Simultaneous Pancreas-kidney Transplants.” CLINICAL TRANSPLANTATION 14.4, part 1 (2000): 340–344. Print.
@article{126402,
  abstract     = {Acute rejection remains a major problem in simultaneous pancreas-kidney (SPK) transplant and occurs in 60-100\% of the cases. With the introduction of mycophenolate mofetil (MMF) replacing azathioprine (AZA) as a basis immunosuppressant, reduced rates of rejection have been reported. This study investigates the frequency and clinical relevance of allograft rejection in SPK patients receiving antithymocyte globulin (ATG) or Basiliximab(R) induction therapy and cyclosporine Neoral(R) (CyA), MMF, steroid basis immunosuppression. Between December 1996 and October 1999, 21 consecutive patients (15 males, 6 females) received a SPK transplant at our institution with a mean +/- standard deviation (SD) age of 42 +/- 6 yr. Of these, 14 patients were treated with anti-thymocyte globulin (ATG) Fresenius(R) (rabbit) 3-5 mg/kg for 6 +/- 2 d, cyclosporine Neoral (CyA) (trough levels 350-400 ng/mL), MMF 3 g/d and low dose steroid therapy. Seven SPK patients were treated with Basiliximab (Simulect(R), Novartis 20 mg on d 0 and d 4 post-transplant) instead of ATG. The patients had an average human leucocyte antigen (HLA) mismatch of 3.9/6 and a negative cross match. All patients remained on triple drug therapy. Three patients were switched to tacrolimus instead of Neoral for CyA intolerance. The mean +/- SD cold ischemia time (CIT) of the organs was 10.1 +/- 2.4 h for the pancreas and 10.5 +/- 2.6 h for the kidney.
Results: Biopsy-proven rejection occurred in the kidney of 1 ATG patient (8\%), which responded to steroid bolus therapy. One of the patients (14\%) with Basiliximab induction developed renal allograft rejection, which was resolved after a 6-d course of anti-CD3 mAb (OKT3) treatment. All patients (100\%) were free from rejection in the pancreas, as measured by urine amylase levels and glycemic control without the need for exogenous insulin with a mean glycosylated hemoglobin (HBA(1)C) of 5.1 +/- 0.7\% and serum creatinine with a mean of 1.24 +/- 0.24 mg/dL in a mean follow-up period of 17 +/- 15 months (median 12, range 2-37).
Conclusion: Triple drug immunosuppression including cyclosporine, MMF and low dose steroids with ATG or interleukin 2 (IL2) receptor antibodies induction therapy appears to be a very suitable immunosuppressive regimen for combined pancreas-kidney transplant (PKT) with a marked reduction in the incidence of rejection.},
  author       = {Hesse, Uwe and Troisi, Roberto and Jacobs, B and Van Vlem, Bruno and de Hemptinne, Bernard and Van Holder, Raymond AMG and Vermassen, Frank and De Roose, J and Lameire, Norbert},
  issn         = {0902-0063},
  journal      = {CLINICAL TRANSPLANTATION},
  keyword      = {Basiliximab,ATG,cyclosporine,mycophenolate mofetil,rejection,simultaneous pancreas-kidney transplant,CADAVERIC KIDNEY,TACROLIMUS,INFECTION,REJECTION},
  language     = {eng},
  number       = {4, part 1},
  pages        = {340--344},
  title        = {A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants},
  url          = {http://dx.doi.org/10.1034/j.1399-0012.2000.140410.x},
  volume       = {14},
  year         = {2000},
}

Altmetric
View in Altmetric
Web of Science
Times cited: